The group addresses the growing complexity and volume of tech-related disputesIRVINE, Calif.--(BUSINESS WIRE)--JAMS, the premier provider of alternative dispute resolution (ADR) services worldwide, ...
Data demonstrate dose‑dependent hearing rescue across multiple mouse modelsCAMBRIDGE, Mass.--(BUSINESS ...
Cash position of €12.0 million as of March 31, 2026Shareholder loan agreement signed with Vester Finance on April 21, 2026, securing a cash runway until the beginning of Q2 2027BioChaperone®: ...
Data from pivotal Phase 3 frontMIND trial evaluating tafasitamab (Monjuvi®/Minjuvi®) in first-line diffuse large b-cell lymphoma (DLBCL) selected for prestigious Plenary Abstracts SessionOral and ...
The company will showcase the latest iRT solution, MIM software innovations, and BK Medical technology – advancing speed, connectivity, and personalized medicine across the cancer care pathway.CHICAGO ...
Medisca, a global leader in personalized pharmaceutical medicine, has entered into a strategic partnership with dsm–firmenich, a leading ingredient manufacturer serving regulated pharmaceutical ...
Joining Infinitopes as CSO and interim COO, Jo Brewer, PhD, an innovator in the field of immunotherapy, will help sustainably scale the company on its journey through clinical development.Expansion of ...
Virta Health’s Nutrition-Based Care Demonstrates Broad, Sustained Reductions in Chronic Inflammation
New peer-reviewed study shows significant improvements across inflammatory markers after one year, demonstrating broad, ...
CyPath® Lung unit sales in April increased nearly 300% compared to April 2025Increasing unit sales for CyPath® Lung continues first quarter 2026 trend of accelerating adoption and clinical ...
Study of 603 PEDD patients and 16,210 non-PEDD patients found PEDD technology was associated with fewer post-procedure complications, reduced hospitalizations, and approximately $7,700 in per-patient ...
Veteran pharma leader and infectious disease pioneer joins QBI to accelerate translation of world-class PPI science into industry partnerships and therapeutic impact–SAN FRANCISCO--(BUSINESS ...
Results from Optimizing Beta-Blocker Dosage in Female Patients Using the Wearable Cardioverter Defibrillator (OPT-BB Women) were presented at ESC-HF 2026CHELMSFORD, Mass.--(BUSINESS WIRE)--ZOLL®, an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results